Moreover, combining JHU‐083 with anti‐PD‐1 antibodies reshapes the tumor microenvironment—reducing suppressive myeloid populations and enhancing CD8+ T‐cell infiltration—thereby improving checkpoint‐blockade efficacy.87 This evidence concerns the gene CD8A and neoplasm.